Histology data builds on growing confidence around Akero’s NASH candidate

Akero’s biopsy data is the positive news the NASH field needed after FDA declined to approve what would have been the first drug for the indication earlier this week.

Akero Therapeutics Inc. (NASDAQ:AKRO) rose $8.45 (34%) to $33.37 on Wednesday after releasing data on secondary histology endpoints from its Phase IIa BALANCED trial after hours Tuesday. The stock move brought the company’s market cap to $957 million...